000227349 001__ 227349
000227349 005__ 20190617200525.0
000227349 0247_ $$2doi$$a10.1016/j.ejca.2017.01.018
000227349 02470 $$2ISI$$a000399856400029
000227349 037__ $$aARTICLE
000227349 245__ $$aA PET-Based Nomogram for Oropharyngeal Cancers
000227349 269__ $$a2017
000227349 260__ $$b10.1016/j.ejca.2017.01.018$$c2017$$aOxford
000227349 300__ $$a9
000227349 336__ $$aJournal Articles
000227349 520__ $$9eng$$aPurpose: In the context of locally advanced oropharyngeal cancer (LAOC) treated with definitive radiotherapy (RT) (combined with chemotherapy or cetuximab), the aims of this study were: (1) to identify PET-FDG parameters correlated with overall survival (OS) from a first cohort of patients; then (2) to compute a prognostic score; and (3) finally to validate this scoring system in a second independent cohort of patients. Materials and methods: A total of 76 consecutive patients (training cohort from Rennes) treated with chemoradiotherapy or RT with cetuximab for LAOC were used to build a predictive model of locoregional control (LRC) and OS based on PET-FDG parameters. After internal calibration and validation of this model, a nomogram and a scoring system were developed and tested in a validation cohort of 46 consecutive patients treated with definitive RT for LAOC in Lausanne. Results: In multivariate analysis, the metabolic tumour volume (MTV) of the primary tumour and the lymph nodes were independent predictive factors for LRC and OS. Internal calibration showed a very good adjustment between the predicted OS and the observed OS at 24 months. Using the predictive score, two risk groups were identified (median OS 42 versus 14 months, p < 0.001) and confirmed in the validation cohort from Lausanne (median OS not reached versus 26 months, p = 0.008).
000227349 6531_ $$aOropharyngeal cancer
000227349 6531_ $$aNomogram
000227349 6531_ $$aPrognostic score
000227349 6531_ $$aPET
000227349 700__ $$aCastelli, J.
000227349 700__ $$aDepeursinge, A.
000227349 700__ $$aNdoh, V.
000227349 700__ $$aPrior, J.O.
000227349 700__ $$aOzsahin, M.
000227349 700__ $$aDevillers, A.
000227349 700__ $$aBouchaab, H.
000227349 700__ $$aChajon, E.
000227349 700__ $$ade Crevoisier, R.
000227349 700__ $$aScher, N.
000227349 700__ $$aJegoux, F.
000227349 700__ $$aLaguerre, B.
000227349 700__ $$aDe Bari, B.
000227349 700__ $$aBourhis, J.
000227349 773__ $$j75$$tEuropean Journal of Cancer$$q222-230
000227349 8564_ $$uhttp://bigwww.epfl.ch/publications/castelli1701.html$$zURL
000227349 8564_ $$uhttp://bigwww.epfl.ch/publications/castelli1701.pdf$$zURL
000227349 8564_ $$uhttp://bigwww.epfl.ch/publications/castelli1701.ps$$zURL
000227349 909C0 $$xU10347$$0252054$$pLIB
000227349 909CO $$ooai:infoscience.tind.io:227349$$qGLOBAL_SET$$pSTI$$particle
000227349 937__ $$aEPFL-ARTICLE-227349
000227349 970__ $$acastelli1701/LIB
000227349 973__ $$rREVIEWED$$sPUBLISHED$$aEPFL
000227349 980__ $$aARTICLE